269 related articles for article (PubMed ID: 27919195)
1. Efficacy and safety of mitoxantrone use in primary and secondary progressive multiple sclerosis - study site experience based on the therapy of 104 patients.
Lasek-Bal A; Bartoszek K; Steposz A; Puz P; Bal W; Kazibutowska Z
Int J Neurosci; 2017 Oct; 127(10):859-863. PubMed ID: 27919195
[TBL] [Abstract][Full Text] [Related]
2. Mitoxantrone for multiple sclerosis.
Martinelli Boneschi F; Vacchi L; Rovaris M; Capra R; Comi G
Cochrane Database Syst Rev; 2013 May; (5):CD002127. PubMed ID: 23728638
[TBL] [Abstract][Full Text] [Related]
3. Mitoxantrone therapy in rapidly worsening multiple sclerosis.
Benesova Y; Stourac P; Beranek M; Kadanka Z
Bratisl Lek Listy; 2005; 106(3):141-3. PubMed ID: 16026151
[TBL] [Abstract][Full Text] [Related]
4. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of mitoxantrone in pediatric patients with aggressive multiple sclerosis.
Etemadifar M; Afzali P; Abtahi SH; Ramagopalan SV; Nourian SM; Murray RT; Fereidan-Esfahani M
Eur J Paediatr Neurol; 2014 Mar; 18(2):119-25. PubMed ID: 24139067
[TBL] [Abstract][Full Text] [Related]
6. Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.
Rivera VM; Jeffery DR; Weinstock-Guttman B; Bock D; Dangond F
BMC Neurol; 2013 Jul; 13():80. PubMed ID: 23841877
[TBL] [Abstract][Full Text] [Related]
7. Immunological studies of mitoxantrone in primary progressive MS.
Pelfrey CM; Cotleur AC; Zamor N; Lee JC; Fox RJ
J Neuroimmunol; 2006 Jun; 175(1-2):192-9. PubMed ID: 16644023
[TBL] [Abstract][Full Text] [Related]
8. Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: a multi-center, retrospective analysis.
Grey Née Cotte S; Salmen Née Stroet A; von Ahsen N; Starck M; Winkelmann A; Zettl UK; Comabella M; Montalban X; Zipp F; Fleischer V; Kruse N; Gold R; Chan A
J Neuroimmunol; 2015 Jan; 278():277-9. PubMed ID: 25468777
[TBL] [Abstract][Full Text] [Related]
9. Mitoxantrone for multiple sclerosis.
Martinelli Boneschi F; Rovaris M; Capra R; Comi G
Cochrane Database Syst Rev; 2005 Oct; (4):CD002127. PubMed ID: 16235298
[TBL] [Abstract][Full Text] [Related]
10. Stability of cognitive functions under mitoxantrone therapy in patients with progressive multiple sclerosis: a pilot analysis.
Schröder A; Klotz P; Lee DH; Gold R; Linker RA
Clin Neurol Neurosurg; 2011 Sep; 113(7):527-30. PubMed ID: 21429658
[TBL] [Abstract][Full Text] [Related]
11. [Mitoxantrone].
Pericot I; Montalban X
Neurologia; 2003; 18(6):318-23. PubMed ID: 12838451
[TBL] [Abstract][Full Text] [Related]
12. Mitoxantrone in worsening secondary progressive multiple sclerosis: A prospective, open-label study.
Khatri BO; Wroblewski M; Kramer J; Dukic M; Poplar A; Anderson AJ
Curr Ther Res Clin Exp; 2006 Jan; 67(1):55-65. PubMed ID: 24678083
[TBL] [Abstract][Full Text] [Related]
13. Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis.
Debouverie M; Vandenberghe N; Morrissey SP; Anxionnat R; Pittion-Vouyovitch S; Vespignani H; Edan G
Mult Scler; 2004 Aug; 10(4):407-12. PubMed ID: 15327038
[TBL] [Abstract][Full Text] [Related]
14. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
Zipoli V; Portaccio E; Hakiki B; Siracusa G; Sorbi S; Amato MP
J Neurol Sci; 2008 Mar; 266(1-2):25-30. PubMed ID: 17870094
[TBL] [Abstract][Full Text] [Related]
15. Mitoxantrone in progressive multiple sclerosis: when and how to treat?
Gonsette RE
J Neurol Sci; 2003 Feb; 206(2):203-8. PubMed ID: 12559512
[TBL] [Abstract][Full Text] [Related]
16. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.
Krapf H; Morrissey SP; Zenker O; Zwingers T; Gonsette R; Hartung HP;
Neurology; 2005 Sep; 65(5):690-5. PubMed ID: 16157900
[TBL] [Abstract][Full Text] [Related]
17. Is there a new place for mitoxantrone in the treatment of multiple sclerosis?
Wawrzyniak S; Rzepiński Ł
Neurol Neurochir Pol; 2020; 54(1):54-61. PubMed ID: 31922582
[TBL] [Abstract][Full Text] [Related]
18. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
[TBL] [Abstract][Full Text] [Related]
19. Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment.
Debouverie M; Taillandier L; Pittion-Vouyovitch S; Louis S; Vespignani H
Mult Scler; 2007 Jun; 13(5):626-31. PubMed ID: 17548442
[TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis: a comparative study.
Perini P; Calabrese M; Tiberio M; Ranzato F; Battistin L; Gallo P
J Neurol; 2006 Aug; 253(8):1034-40. PubMed ID: 16609811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
